Compare TWIN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | RCEL |
|---|---|---|
| Founded | 1918 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 306.5M |
| IPO Year | 1994 | 2018 |
| Metric | TWIN | RCEL |
|---|---|---|
| Price | $24.40 | $10.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 93.6K | ★ 424.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 1428.57 | 27.20 |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $381,270,000.00 | $71,610,000.00 |
| Revenue This Year | $10.79 | $17.17 |
| Revenue Next Year | $8.43 | $49.82 |
| P/E Ratio | $13.55 | ★ N/A |
| Revenue Growth | ★ 11.90 | 11.45 |
| 52 Week Low | $12.79 | $3.22 |
| 52 Week High | $25.50 | $11.39 |
| Indicator | TWIN | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 66.99 |
| Support Level | $21.76 | $3.70 |
| Resistance Level | N/A | $10.77 |
| Average True Range (ATR) | 1.34 | 0.60 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 72.84 | 59.11 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.